1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21925
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDirix, L. Y.en
dc.contributor.authorTonnesen, F.en
dc.contributor.authorCassidy, J.en
dc.contributor.authorEpelbaum, R.en
dc.contributor.authorten Bokkel Huinink, W. W.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorSorio, R.en
dc.contributor.authorGamucci, T.en
dc.contributor.authorWolff, I.en
dc.contributor.authorTe Velde, A.en
dc.contributor.authorLan, J.en
dc.contributor.authorVerweij, J.en
dc.date.accessioned2015-11-24T19:19:04Z-
dc.date.available2015-11-24T19:19:04Z-
dc.identifier.issn0959-8049-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21925-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Agents/*adverse effects/therapeutic useen
dc.subjectAziridines/*adverse effects/therapeutic useen
dc.subjectBreast Neoplasms/*drug therapyen
dc.subjectColorectal Neoplasms/drug therapyen
dc.subjectDigestive System Neoplasms/*drug therapyen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subject*Indolequinonesen
dc.subjectIndoles/*adverse effects/therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPancreatic Neoplasms/drug therapyen
dc.subjectProteinuria/chemically induceden
dc.subjectStomach Neoplasms/drug therapyen
dc.titleEO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Groupen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8943690-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1996-
heal.abstractIn a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m2. 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied.en
heal.journalNameEur J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons